The JNK Signaling Pathway in Inflammatory Skin Disorders and Cancer

• Published in: Cells (Basel, Switzerland) Vol. 9; no. 4; p. 857
• Main Authors: Hammouda, Manel B, Ford, Amy E, Liu, Yuan, Zhang, Jennifer Y
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 02-04-2020; MDPI
• Subjects: Apoptosis; Basal cell carcinoma; BCC; c-Jun protein; Cell differentiation; Cell growth; Cell proliferation; Cell survival; Fibrosis; Humans; JNK; JNK Mitogen-Activated Protein Kinases - metabolism; JNK protein; JNK3 protein; keratinocytes; Kinases; MAP kinase; Melanoma; Mutation; Neoplasms - genetics; Psoriasis; Review; SCC; Scleroderma; Signal Transduction; Skin diseases; Skin Diseases - genetics; skin inflammation; Squamous cell carcinoma; Transcription factors; Tumor necrosis factor-TNF; SCC; BCC; JNK; psoriasis; scleroderma; melanoma; fibrosis; keratinocytes; skin inflammation
• ISSN: 2073-4409; 2073-4409
• DOI: 10.3390/cells9040857

The c-Jun N-terminal kinases (JNKs), with its members JNK1, JNK2, and JNK3, is a subfamily of (MAPK) mitogen-activated protein kinases. JNK signaling regulates a wide range of cellular processes, including cell proliferation, differentiation, survival, apoptosis, and inflammation. Dysregulation of JNK pathway is associated with a wide range of immune disorders and cancer. Our objective is to provide a review of JNK proteins and their upstream regulators and downstream effector molecules in common skin disorders, including psoriasis, dermal fibrosis, scleroderma, basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma.